P21

P21 (also known as P021) is a synthetic peptide derived from a portion of the CNTF (ciliary neurotrophic factor) protein. It is a newer research compound with a specific focus on brain health and cognitive function. How it works: P21 boosts brain-derived neurotrophic factor (BDNF) and promotes neurogenesis - the growth of new neurons. BDNF is central to memory formation, learning, and mood stability, so compounds that raise it have been of significant interest in neuroscience research. Who tends to use it: People with cognition goals - particularly focus and memory - at a primary level. It also carries a minor supportive rating for mood. P21 is at the early stage of the compound's development arc, so it tends to attract people who are informed about the peptide research space and are comfortable with limited human data. How it is taken: P21 can be administered either intranasally or by subcutaneous (SC) injection. Dosing is per protocol - no general range is published because the human experience base is still being established. It is taken in the morning, daily, in short cycles. Exact dose and duration are determined at consult. What to expect: This is an early-stage compound. The evidence is classified as anecdotal. Effects, if experienced, align with what BDNF elevation tends to produce - improved memory consolidation and mood stability over the course of a cycle, rather than an immediate noticeable shift. Safety: The record describes P21 as an early-stage compound. There are no excludeIf flags - no listed contraindications for pregnancy or cancer history. That absence reflects the limited data rather than a confirmed clean safety profile, so clinical review is particularly important here. Your licensed provider in the PepDepo network will evaluate whether P21 is appropriate and will set your protocol at consult.